Vascular smooth muscle intracellular targets

Vascular smooth muscle intracellular targets encompass a diverse array of signaling molecules and pathways within vascular smooth muscle cells (VSMCs) that regulate vascular tone, structural remodeling, and phenotypic plasticity. Key components include enzymes like soluble guanylate cyclase (sGC) and phosphodiesterases (PDEs), which modulate cyclic nucleotide levels (cGMP and cAMP), and kinases such as Rho-associated protein kinase (ROCK) and myosin light chain kinase (MLCK), which control the phosphorylation state of the contractile apparatus. These targets are critical in the pathogenesis of cardiovascular diseases, including hypertension, pulmonary arterial hypertension, and atherosclerosis, where dysregulation leads to excessive vasoconstriction or maladaptive cell proliferation. Pharmacological intervention at these sites—using agents like nitrates, PDE inhibitors, and ROCK inhibitors—allows for precise control of vascular resistance and the prevention of vascular remodeling. Understanding these intracellular mechanisms is essential for developing therapies that can bypass surface receptors to directly influence the contractile and proliferative state of the vessel wall.

Other names

Intracellular signaling pathways of vascular smooth muscleVSMC intracellular targetsContractile apparatus regulatory proteinsVascular smooth muscle signaling effectors

Stimulation of soluble guanylate cyclase (sGC) to increase cGMP; inhibition of phosphodiesterases (PDE3, PDE5) to prevent cyclic nucleotide degradation; inhibition of Rho-associated protein kinase (ROCK) to decrease calcium sensitivity; modulation of myosin light chain kinase (MLCK) and phosphatase (MLCP) activity; and regulation of intracellular calcium release from the sarcoplasmic reticulum.